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KEY POINTS 
Question: Does trimetazidine improve exercise capacity in hypertrophic cardiomyopathy? 
Findings: this single center, randomized, placebo-controlled, double-blind clinical trial found oxygen 
consumption at peak exercise was not improved by 3 months of oral trimetazidine therapy.  
Meaning: In spite of early promise, metabolic modulators have limited application in HCM. 
 
TWEET (71 characters) 
Trimetazidine does not improve exercise capacity in non-obstructive HCM  
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ABSTRACT 
Importance: Hypertrophic cardiomyopathy (HCM) causes limiting symptoms, mediated partly via 
inefficient myocardial energy utilisation. Inhibitors of myocardial fatty acid metabolism may improve 
exercise tolerance in patients with HCM. 
Objective: To determine the effect of oral therapy with trimetazidine–a direct inhibitor of fatty acid 
beta-oxidation–on exercise capacity in patients with symptomatic non-obstructive HCM. 
Design: A randomized, placebo-controlled, double-blind clinical trial. 
Setting: Single tertiary center 
Participants: 51 drug-refractory symptomatic (NYHA Class ≥ 2) patients aged 24 to 74 years with a 
maximum left ventricular outflow tract gradient < 50 mmHg and a peak oxygen consumption (peak 
VO2) during exercise ≤ 80% predicted value for age and sex. 
Intervention: Participants were randomly assigned to trimetazidine 20 mg three times daily (n=27) or 
placebo (n=24) therapy for 3 months. 
Main outcome: The primary endpoint was peak VO2 during upright bicycle ergometry. Secondary 
endpoints were: 6-minute walk distance, quality of life (Minnesota living with heart failure 
questionnaire), frequency of ventricular ectopics, diastolic function and serum NT-proBNP and 
troponin T. 
Results: 49 participants (age 50 ± 13 years, 70 % male) who received trimetazidine (n=26) or placebo 
(n=23) completed the study. Trimetazidine therapy was not associated with improved exercise 
capacity. After adjusting for baseline values, peak VO2 was 1.35 ml/kg/min lower (95% CI 2.58 to 0.11, 
p=0.033) in the intervention group after 3 months. 
Conclusion and relevance: In symptomatic patients with non-obstructive HCM, trimetazidine therapy 
does not improve exercise capacity. 
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INTRODUCTION 
 
Scientific background and explanation of rationale 
Hypertrophic cardiomyopathy (HCM) is defined clinically by the presence of left ventricular 
hypertrophy unexplained by loading conditions; it predisposes to sudden cardiac death and 
progressive heart failure (1). In most patients, it is an autosomal dominant genetic trait caused by 
mutations cardiac sarcomere protein genes (2). Individuals with exertional symptoms caused by left 
ventricular outflow tract obstruction (LVOTO) can be treated with drugs or septal reduction therapy. 
Similar symptoms occur in the absence of LVOTO but medical treatment is often ineffective (1).  
Many of the gene mutations that cause HCM increase  the energetic cost of cardiomyocyte contraction 
and relaxation (3). Conventional therapies, such as beta-blockers and non-dihydropyridine calcium 
antagonists, reduce myocardial energy demands by decreasing heart rate and blood pressure, but 
their use is limited by side-effects or lack of clinical efficacy. An alternative approach is to stimulate 
glucose oxidation and reduce fatty acid oxidation through  inhibition of fatty acid uptake into the 
mitochondrion and direct inhibition of β-oxidation (4). Compared to placebo, perhexiline (a carnitine 
palmitoyl transferase-1 (CPT-1) inhibitor) was shown to improve symptoms and exercise performance 
in HCM  associated with improved myocardial energetics and diastolic filling (5). However, perhexiline 
is limited by its narrow therapeutic index and potential neuro- and hepatotoxicity when patients are 
exposed to sustained high plasma levels of the drug. We hypothesized that trimetazidine 
dihydrochloride, a safe and well tolerated direct inhibitor of β-oxidation, improves symptoms and 
exercise capacity in patients with non-obstructive HCM. 
 
Specific objectives/hypothesis: To assess the effects of trimetazidine in medically refractory 
symptomatic patients with non-obstructive HCM.  
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METHODS: 
Trial design: The study was a non-commercial, investigator led, single center randomized, double-
blind, placebo-controlled, parallel-group design of 3 months duration (ClinicalTrials.gov Identifier: 
NCT01696370). The study was approved by the National Research Ethics Committee (11/AL/0161) and 
participants provided written informed consent prior to enrolment. Participants were allocated to 
placebo or intervention in a ratio of 1:1. The study was conducted according to the principles of the 
Declaration of Helsinki and monitored by an independent data and safety monitor. 
Participants: Eligible participants were ≥ 18 years of age with a diagnosis of HCM on stable medical 
therapy. Participants were symptomatic (NYHA class ≥ 2) with reduced exercise capacity during 
symptom limited bicycle ergometry defined by peak oxygen consumption (peak VO2) ≤ 80% of 
predicted values for age and sex. Individuals with diabetes mellitus, renal impairment (eGFR < 60 
ml/min) or liver impairment were excluded. After trial commencement, eligibility criteria were 
amended to include patients with LVOTO < 50mmHg (instead of < 30 mmHg) and individuals with 
permanent atrial fibrillation and a ventricular rate (< 90 bpm). This was to improve recruitment of 
more symptomatic drug refractory patients.  
Interventions: After baseline evaluation, patients were randomized in a double-blind fashion, to 
receive either trimetazidine 20 mg (n=27) or placebo (n=24) three times daily. No dose adjustments 
were made. Concomitant medications were continued for the trial duration. 
Outcomes: The primary end-point was peak VO2. Secondary end points were: a) symptom status 
assessed by the Minnesota living with heart failure questionnaire (MLHFQ) (6); b) exercise capacity 
assessed by 6-minute walk distance and the sub-maximal cardio-pulmonary exercise parameter 
VE/VCO2 slope c) biomarkers: N-terminal pro brain natriuretic peptide (NT-proBNP), troponin T, 
insulin/glucose ratio and HOMA-IR (Homeostatic Model Assessment of Insulin Resistance). d) systolic 
and diastolic function on echocardiography and e) ventricular ectopics on 24-hour ambulatory 
monitoring. Investigations were performed at baseline and 3 months. The study design is shown in 
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Supplementary Figure 1. No changes were made to primary or secondary endpoints after the trial 
commenced. Adverse events were assessed at the 4-week telephone call and 3-month follow-up visit. 
Sample size: 72 patients (36 in each group) were required to detect a change in peak VO2 of 2 
ml/kg/min (power of 80% and significance level 5%) using a two-sample t-test. An estimated standard 
deviation (SD) of 3 ml/kg/min was used in the calculation (5).   
Randomization: A blinded internet randomization service supplied by Sealed Envelope™ was used 
with linked randomization list for administrator un-blinding. Participants, researchers and clinicians 
were blinded to treatment.  
Statistical methods: Data were analyzed with STATA (Version 14). Analyses were carried out by 
treatment allocated, using all available data (complete case) with intention to treat principles.  
Continuous variables were summarized using mean ± SD or median and interquartile range (IQR).  
Categorical variables were presented as frequencies and percentages. A linear regression model, 
adjusting for baseline peak VO2 was used to estimate the treatment effect on the primary outcome. 
Appropriate regression models were used for the secondary outcomes, adjusted for baselines values. 
A p-value < 0.05 was taken to indicate statistical significance.  
RESULTS 
Recruitment: All participants were recruited from cardiomyopathy clinics at The Heart Hospital, 
University College London Hospitals, London, UK between 31st May 2012 and 8th September 2014. A 
total of 51 patients were randomized: 24 in the intervention group and 27 in the control group. One 
patient withdrew from the study and another was excluded from final analysis because of poor 
compliance. Figure 1 summarizes  participant flow through the study. Recruitment was incomplete at 
the end of the pre-specified enrolment period despite a 6-month extension and protocol 
amendments. With agreement from the sponsor and an independent advisor we undertook an interim 
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statistical analysis. The trial was terminated on 14th April 2015. Reasons for screen failure are 
summarized in Supplementary Table 1.  
 
Baseline data:  Patient demographics and baseline clinical variables are shown in Table 1. The 
trimetazidine and placebo groups were well matched. 
Outcomes and estimation: The effects of placebo and trimetazidine on the primary and secondary 
outcomes are shown in Supplementary Table 2 and 3. Peak VO2 increased from 17.36 ± 3.59 to 19.01 
± 4.68 ml/kg/min in the placebo group and from 17.35 ± 3.89 to 17.66 ± 3.53 ml/kg/min in the 
trimetazidine group. After adjusting for baseline peak VO2, the trimetazidine group had a lower peak 
VO2 by 1.35 ml/kg/min (95% CI -2.58 to -0.11, p = 0.033 (Table 2).  Inspection of the distribution of 
residuals and residuals versus fitted values did not indicate a violation of the assumptions of linear 
regression. Figure 2 shows individual changes in peak VO2. 
Exercise capacity: On average, patients in the trimetazidine group walked 38 meters (95% CI -5 to -72) 
less than patients in the placebo group at 3 months after adjusting for their baseline walking distance 
measurements. The median VE/VCO2 slope was higher by 0.13 (95% CI -1.52 to 1.77) (Table 2 and 3).   
Symptom status: At 3 months, the adjusted MLHFQ score, adjusting for the baseline values, was lower 
in the trimetazidine group by 0.8 (95% CI -9.2 to 7.7)  
Echocardiography: After adjusting for the baseline values, there was no change in adjusted diastolic 
function, LV ejection fraction, left atrial size or global LV longitudinal systolic strain. 
Biomarkers: After adjusting for the baseline values, there was no change in adjusted log NTproBNP 
and Troponin T at 3 months in the trimetazidine group.  The insulin/glucose ratio and HOMA-IR fell in 
the trimetazidine group indicating improved insulin sensitivity consistent with the known effects of 
trimetazidine (Table 2 and 3). 
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Arrhythmia: The odds of having more than 500 ventricular ectopics at 3 months in the Trimetazidine 
group was 0.5 times the odds in the placebo group (95% CI 0.04-6.96).  
 
Adverse events: Two serious adverse events (SAEs) affecting a single patient in the placebo group) 
were recorded (chest pain and respiratory tract infection requiring hospital assessment). Non-serious 
adverse events are summarized in Supplementary Table 4.   
 
DISCUSSION 
The myocardium depends on oxygen for high-energy phosphate (adenosine triphosphate (ATP)) 
production by oxidative phosphorylation. In the normal heart, ATP is produced primarily by the 
metabolism of free fatty acids (FFAs) and carbohydrates, with FFAs accounting for approximately 70% 
of ATP production in the fasting state (4). In health, FFA oxidation is directly related to plasma FFA 
concentration, whereas glucose and lactate uptake are inversely related to plasma FFA levels via the 
Randle effect. Importantly, FFAs are less efficient as a source of myocardial energy as they require 
approximately 10% more oxygen than glucose in order to produce an equivalent amount of ATP (4). 
HCM is characterized by a reduction in the concentration of high-energy phosphates in the 
myocardium (4, 7) possibly due to myocardial ischemia or an energy wasting effect of sarcomere 
protein gene mutations (8, 9).  
Fatty acid oxidation is regulated by the concentration of plasma FFAs, activity of CPT-1 and β-oxidation 
in the mitochondria. Drugs that inhibit cardiac fatty acid oxidation act in one of three ways: 
suppression of fatty acid release from adipocytes (e.g. beta-blockers); inhibition of CPT-I and fatty acid 
uptake into the mitochondria (e.g. perhexiline); and direct inhibition of β-oxidation (e.g. trimetazidine 
and ranolazine).  
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Trimetazidine, a reversible competitive inhibitor of 3-ketoacyl-coenzyme A thiolase has a good safety 
and tolerability profile and in placebo-controlled trials has been shown to improve exercise 
performance in patients with stable angina and ischemic cardiomyopathy (10-12). Trimetazidine 
appears to reduce free radical production and prevents accumulation of protons, sodium, and calcium 
in the myocyte (13).  
In this study, we demonstrated no beneficial effect of trimetazidine on exercise capacity in patients 
with HCM. A negative result was also reported with ranolazine in HCM (14). This may reflect the 
weaker inhibition of fatty acid metabolism compared to CPT-1 inhibitors or that the 3-month duration 
of therapy was insufficient to improve symptoms. The fact that there was a 2 ml/kg/min increase in 
the placebo group could potentially represent a harmful effect of the drug but the change was within 
the 95% confidence interval of the study design.  
Limitations: The study was stopped before the end of planned recruitment due to unanticipated 
reluctance for patients to participate because of travel distance and work commitments. The sample 
size in both arms was small so the power to examine the association between baseline characteristics 
and outcomes was limited. There was no measure of blood trimetazidine concentration, so 
compliance was assessed by diary card and pill counting. 
Conclusions 
Trimetazidine therapy does not improve exercise capacity in symptomatic patients with non-
obstructive HCM. 
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OTHER INFORMATION 
Trial registration: https://clinicaltrials.gov/ct2/show/NCT01696370 
Protocol: The protocol is available from the sponsor. Biomedical Research Centre Research & 
Development, Maple House Suite A 1st floor, 149 Tottenham Court Road, London W1T 7DN 
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Figure 1. Flow diagram of the study cohort 
Abbreviations: N/A not applicable 
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Figure 2. Study primary outcome. The effects of placebo and trimetazidine on exercise capacity. 
Peak VO2 increased from 17.36 ± 3.59 to 19.01 ± 4.68 ml/kg/min in the Placebo group and from 
17.35 ± 3.89 to 17.65 ± 3.53 ml/kg/min in the Trimetazidine group.  
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Table 1.  Descriptive statistics for baseline variables in 51 patients. Categorical variables are 
described as number (%) and continuous variables as median (IQR, interquartile range) or mean ± 
standard deviation (range). 
Abbreviations: BP blood pressure, CRT cardiac resynchronisation therapy,  
 Trimetazidine (n=27) Placebo (n=24) 
Male 18 (67%) 18 (75%) 
Caucasian 17 (63%) 19 (79%) 
Age (years) 49 ± 13 (25 - 69) 51 ± 14 (24 - 74) 
Weight (kg) 87 ± 23 (47 - 132) 87 ± 18 (49 - 133) 
Height (cm) 171 ± 10 (155 - 191) 175 ± 10 (153 - 192) 
Body Mass Index (kg/m2) 29 ± 6 (18 - 42) 28 ± 5 (21-38) 
Pulse (beats per minute) 69 ± 11 (50 - 88) 69 ± 10 (51 - 85) 
Systolic BP (mmHg) 118 ± 15 (90 - 151) 120 ± 19 (92 - 173) 
Diastolic BP (mm Hg) 73 ± 9 (56 - 87) 72 ± 6 (62 - 89) 
Creatinine (µmol/L) 90 ± 18 (50 - 131) 83 ± 13 (60 - 105) 
Haemoglobin (g/L) 14.7 (IQR 13.7 - 15.4) 14.7 (IQR 13.9 – 15.5) 
Current or ex-smoker 19 (70%) 14 (58%) 
Alcohol (units per week) 5 ± 8 (0 - 30) 8 ± 9 (0 - 40) 
Electrocardiogram 
   Sinus rhythm 
   Atrial Fibrillation 
   Paced rhythm 
 
18 (69%) 
2 (8%) 
6 (22%) 
 
17 (71%) 
4 (17%) 
3 (12%) 
QRS interval (msec) 122 ± 34 (82 - 212) 126 ± 35 (80 - 194) 
Medical History   
Hypertension 5 (19%) 0 (0%) 
Paroxysmal atrial fibrillation 1 (4%) 1 (4%) 
Implantable Cardioverter Defibrillator 11 (41%) 12 (50%) 
Septal myectomy 5 (19%) 8 (33%) 
Alcohol septal ablation 1 (4%) 2 (8%) 
CRT device 1 (4%) 0 (0%) 
Concomitant Medication   
Bisoprolol 12 (44%) 10 (42%) 
Verapamil 9 (33%) 5 (21%) 
Disopyramide 1 (4%) 3 (13%) 
Aspirin 12 (44%) 5 (21%) 
Clopidogrel 1 (4%) 1 (4%) 
Warfarin 10 (37%) 13 (54%) 
Spironolactone 8 (30%) 11 (46%) 
Simvastatin 5 (19%) 3 (13%) 
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Table 2. Mean difference (95%CI) in outcome comparing TMZ and Placebo after adjustment for 
baseline outcome value (unless otherwise stated) 
Abbreviations: LVOT left ventricular outflow tract, NTproBNP N-terminal pro brain natriuretic peptide, 
VEs ventricular ectopics, VE ventilation, VCO2 carbon dioxide production, VO2 oxygen production.  
 
Outcome at 3 months Mean difference (95%CI) p-value 
Primary outcome 
Peak VO2 (ml/kg/min)  
-1.35 (-2.58, -0.11) 0.033 
6 min walking distance (metres) -38.4 (-71.70, -5.13) 
 
VEs > 500 /24 hours 0.49* (0.035-6.96)  
Minnesota heart failure score  -0.77 (-9.22, 7.68) 
 
Grade of diastolic function  0.89** (0.15, 5.49) 
 
LV ejection fraction (%) 0.72 (-2.45,3.88) 
 
Left Atrial Area (cm sq.) -0.95 (-3.16, 1.26) 
 
Global Systolic Strain  -0.07 (-1.40, 1.26) 
 
Left atrial volume index (mls/m2) −0.909  (−7.45, 5.64)  
Log NT pro BNP (pmol/L) 0.07 (-0.28,0.14) 
 
Troponin T (ng/L) 0.001 (-0.013,0.016) 
 
Insulin/Glucose ratio  0.14*** (0.77, 1.05) 
 
VEVO2 Slope -0.74 (-3.76, 2.28) 
 
VO2 Work Slope 0.009 (-1.09, 1.11) 
 
VEVCO2  0.13 (-1.52,1.78) 
 
 
*Odds Ratio comparing TMZ group to Placebo (based on logistic regression) 
** Odds Ratio comparing TMZ group to Placebo (based on ordinal regression) 
***Median difference after adjusting for baseline values (based on quantile regression) 
 
 
